Despite the commercial challenges which were present throughout 2013, the global performances of the medical technology and biotechnology industry remain constant, maintaining the relatively low growth levels from the past few years. Nevertheless, while the industry is facing the pressure made by the market and the regulatory authorities, a new challenge is threatening the perspectives for growth: standardization, according to the annual EY study, Pulse of the industry: differentiating differently.
For more information, please see the Romanian version of the article, here.
